SCHEMBL2401328

SCHEMBL2401328

CCSCCNC(=O)C1=NOC2(CCN(S(=O)(=O)N(C)C)CC2)C1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.34
SLC6A9 P48067 1/20 0.34
PKM P14618 1/20 0.33
LMNA P02545 1/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
ITGB3 P05106 3/20 0.32
ITGB1 P05556 3/20 0.32
ITGAV P06756 3/20 0.32
ITGA2B P08514 3/20 0.32
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
APOBEC3A P31941 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
ITGA5 P08648 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411323 0.83 GAA (0.35) GAASLC6A9ALDH1A1MEN1KMT2A
SCHEMBL2400415 0.81 MEN1 (0.46) GAASLC6A9RAB9ANPC1ALDH1A1
SCHEMBL2401314 0.80 NPSR1 (0.43) SLC6A9LMNARAB9ANPC1ALDH1A1
SCHEMBL2399115 0.78 SMN1; SMN2 (0.38) GAALMNAGPR119ALDH1A1MEN1
SCHEMBL2400943 0.76 KDM4E (0.50) MEN1KMT2A
SCHEMBL2404743 0.75 PKM (0.42) PKMLMNAGPR119KMT2A
SCHEMBL2579293 0.74 EPHX2 (0.40) GAARAB9ANPC1GPR119ALDH1A1
SCHEMBL2400830 0.72 P2RX7 (0.40) GAASLC6A9LMNARAB9ANPC1
SCHEMBL2581246 0.71 NAMPT (0.43) LMNARAB9AGPR119ALDH1A1
SCHEMBL2400879 0.71 POLB (0.48) GAAPKMLMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 GAA 1186/4885SLC6A9 4301/4885PKM 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.